Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How can a big pharma "steal" Brilacidin for a few dollars? Of the outstandinng shares issued, not many of them are for sale at the current share price. Certainly, Leo is not going to sell for a few dollars.
By now the research referenced in that press release by IPIX most certainly has been done. If Brilacidin demonstrated effectiveness, the scientists involved should be highly vocal right about now given this new Monkey Pox outbreak. It simply cannot be ignored. We shall see.
Based on this news ... "Afinum announces the formation of the MedTech Laser Group via acquisition of A.R.C. Laser and neoLaserLtd.,Gil Shapira, to jointly invest in the formation of an integrated champion for medical laser technologies. As part of the transaction, Afinum acquires a significant majority stake while the founders re-invest in the newly formed entity." And so -- when BeaMed gets approval for their StingRay Laser system, they will be integrated into the MedTech Laser Group as they would be a perfect fit. The stars seem to be aligned!
Thanks to frenchbroad and sit tight . Always informative.
This from the Nature article: "Brilacidin alone was shown to inhibit the growth of C. neoformans, acting as a fungicidal drug, but surprisingly also potentiated the activity of caspofungin (CAS) against this species. We investigated the mechanism of action of BRI and BRI + CAS against C. neoformans. We propose BRI as a new antifungal agent against cryptococcosis." You better believe that there are now plenty of eyeballs alert to this amazing drug. One of the big-boy pharma companies will snatch it up without a doubt. It will only get more expensive as time goes by.
This should quickly patch things up between Leo and Gill. "Busting Cryptococcus with Brilacidin" written by the senior editor of Research Highlights.
This journal has a 2023 impact factor of 69.2, ranking it 1st out of 135 journals in the "Microbiology" category.
Extreme credibility vs. anonymous banned poster. Obviously huge value here that can not and will not be ignored given the massive humanitarian worldwide need.
THANK YOU, SitTight!
What doesn't ring true to me is that rather than go bankrupt, Leo has enough financial resources that if he loses in court he could loan IPIX the money and pay up and eliminate that issue so that the IPIX.BeaMed alliance can move forward. Leo would quickly recoup his money via salary and profits and repayment of the loan.. imo.
A BeaMed/IPIX scenario I read that makes sense:
A Payor Analysis began in May of 2022 regarding the use of Brilacidin in treating oral mucositis.
On June 15,2022 Leo announced the investment in Squalus/BeaMed.
On July 22 or so Leo announced the results of the Payor Analysis in a PR and the results were very good. We haven’t heard a word since then about OM. Why?
It is unlikely that this investment/reverse merger deal with BeaMed wasn’t just about the $4,000,000 and IPIX 35% cut, but the value of OM going forward and how much that could be worth to the merged company.
Leo proved the value of Brilacidin for OM to BeaMed, and a deal was signed. IPIX will go it alone with OM using BeaMed money or the SP will be high enough after the merger or the 510 FDA approval (which ever comes 1st) to invoke the Aspire deal or they do another financial deal. Considering the war in Israel, progress may have been slower than had been anticipated.
PJ, I just took at look, and the board views are at 52,634 at 4:55 p.m. The last post on the hangout was over a month ago. I don't know how those numbers of eyeballs are possible given where we are currently. I sure hope they are accurate, but it seems crazy.
Brilacidin is very much alive and well. "Brilacidin's efficacy against fungi had not been comprehensively explored until my studies, which showcased its viability as a therapeutic agent against challenging-to-treat fungal infections, thereby offering a beacon of hope for future clinical interventions."
For so many months this poster has been putting time in every day claiming that IPIX is "dead." If it were so, he would have moved through the five stages of grief and moved on instead of wasting his time. The fact that he has not, refutes his false assertion.
frenchbroad, you said, "They are one of many companies who sell Brilacidin." There is no question that IPIX is receiving a massive amount of attention with their amazing Brilacidin. It's good to hear that it has begun to translate into some revenue, and is sure to ramp up for the treatment of multiple indications going forward.
Pete, congrats on your books. I could not find your email address in your profile.
Nearly 5000 views already this morning on that message board, but practically no post activity for quite some time. The number of views ramping up so quickly tells me there is now a much greater awareness and interest in IPIX. The big question is why? Thousands of people are now checking in waiting for positive news to be announced, imo. I like that there is a minuscule number of shares being traded with no chance of any major accumulation as investors shares are not for sale. When positive news breaks, buying will be a free-for-all.
PJ, I just checked and the IPIX views are now 6,522. That sort of activity demonstrates a huge amount of interest in this so-called "dead" company.
Logically, if these individuals really believed that IPIX is dead and worthless they would be gone... unless... their incentive for spending so much time here every day echoing their doom and gloom mantra is quite opposite from the content of the messages they post. Obviously, the answer is the latter of those two choices, imo.
So true. Simple logic.
The cabal of IPIX dissidents have their orders. By any means necessary, this company must be destroyed! If this tiger gets out of its cage, it will eat us for lunch.
A little hyperbole, but you get the message.
Correct. Only the brain dead would waste their time if they believed that IPIX was worthless. Their work continues unabated day after day because they know better.
For a security to become worthless, it not only needs to have no value, but it needs to have no potential to regain value. These recent radical fluctuations on very low volume to me are meaningless with IPIX currently on the Expert market. Brilacidin and BeaMed have the potential to regain great value, and it could happen literally over night.
Anything positive about IPIX must be killed. Remember, the company is "dead."
"We propose BRI as a new antifungal agent against cryptococcosis." CMC, You're right. I forgot to add the best part!!
"My advice is to block the moderators and don’t waste your time reading their infantile lies."
I blocked them long ago.
Thanks for sharing that information that contradicts the often repeated falsehood that the company is "dead." My favorite part is "Brilicidin alone was shown to inhibit the growth of C. neoformans, acting as a fungicidal drug at concentrations of 2.5 µM, but surprisingly also potentiated the activity of CAS against this species. We have demonstrated that BRI is potentially an important antifungal agent against cryptococcosis, particularly important for synergizing with CAS, which is otherwise ineffective against this pathogen."
https://www.biorxiv.org/content/10.1101/2024.04.10.588976v1.full
At this juncture in the history of my investment in IPIX, I believe that everything hinges upon our equity position and alliance with BeaMed Technologies, LTD.
If there is anyone on this message board that is not familiar with their amazing StingRay laser system, check out their home page. Absolutely massive revenue potential, and they are not far away from being ready to go to market in the near future. I said it before as have other investors here: A reverse merger with BeaMed and a name change with a new CEO is highly likely. If and when that happens, investors will be scrambling to buy in.
THAT'S A FABOLOUS FIND!!!
From this point going forward, imo it is all about the relationship between IPIX and BeaMed Technologies, Inc. and what I consider to be the strong likelihood of a reverse merger. I will not attempt a guess as to the timing of the news of such an event, but remain super confidant it will happen. IPIX investors who have been paying attention are well aware of the huge potential of this alliance going forward.
There are 'crack addicts' and there are 'crap addicts.' The posts reveal which of those addictions apply.
The tractors don't mention the tremendous potential IPIX investors have with our large equity stake in BeaMed Technologies.
The answer to that question is obvious. We just don't know the details. As an anonymous non-investor posting thousands of times here for years, I imagine it must be a tiresome gig by now. It will terminate with the first deal to be announced, and he/she will be vaporized into the netherworld of cyberspace.
But not BeaMed Technologies, LTD. Standby for positive news soon on that front.
And why would Leo waste his time talking to a non-investor? It didn't happen.
Loanranger was unmasked years ago, but continues to persist with his/her negative agenda as evidenced by this non-investor's many thousands of posts on this message board. It's not hard to figure out.
You are embarrassing yourself with your repeated false claims that Innovation Pharmaceuticals is a "dead" company as the share price steadily rises. Time to come up with a new approach to bashing the company imo.
The short investors didn't want to get squeezed. They took their profit and closed out nearly all their positions because they clearly see what is soon coming: positive news with IPIX and/or BeaMed. Simple as that, imo
Bozo, you are a non-investor criticizing an investor in IPIX. Mind your own business.
He/she is just another bozo on the basher bus.
I bet he/she was an obnoxious know-it-all in school. 😜
More on the amazing BeaMed Laser System:
WAKEFIELD, MA / ACCESSWIRE / June 15, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today announced that the Company has acquired a minority stake in Israel-based Squalus Medical, the inventor and developer of the Sting Ray Laser System (the "StingRay System"), a novel laser-based thermal ablation technology designed for treatment of previously inoperable cases of epilepsy and for improvement of outcomes and enablement of new treatment options for oncology procedures, including those treating brain, prostate, liver, breast and lung cancers.
The StingRay System combines new fiber optic technology with an advanced laser console and computerized intelligent control that allows an excellent match between the structure of tumors and epileptic focal points and the energy delivery, while protecting vital functional areas against thermal damage. The console integrates advanced imaging modalities, and guides the physician, making sure the treatment is adjusted to the specific patient needs with real time energy control.
The StingRay System is supported by Squalus' proprietary technologies that deliver remarkable properties for controlling laser energy.